183 related articles for article (PubMed ID: 29478075)
1. Cancer evolution, mutations, and clonal selection in relapse neuroblastoma.
Schulte M; Köster J; Rahmann S; Schramm A
Cell Tissue Res; 2018 May; 372(2):263-268. PubMed ID: 29478075
[TBL] [Abstract][Full Text] [Related]
2. Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions.
Schmelz K; Toedling J; Huska M; Cwikla MC; Kruetzfeldt LM; Proba J; Ambros PF; Ambros IM; Boral S; Lodrini M; Chen CY; Burkert M; Guergen D; Szymansky A; Astrahantseff K; Kuenkele A; Haase K; Fischer M; Deubzer HE; Hertwig F; Hundsdoerfer P; Henssen AG; Schwarz RF; Schulte JH; Eggert A
Nat Commun; 2021 Nov; 12(1):6804. PubMed ID: 34815394
[TBL] [Abstract][Full Text] [Related]
3. Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone.
Abbasi MR; Rifatbegovic F; Brunner C; Mann G; Ziegler A; Pötschger U; Crazzolara R; Ussowicz M; Benesch M; Ebetsberger-Dachs G; Chan GCF; Jones N; Ladenstein R; Ambros IM; Ambros PF
Clin Cancer Res; 2017 Aug; 23(15):4224-4232. PubMed ID: 28228384
[No Abstract] [Full Text] [Related]
4. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
[TBL] [Abstract][Full Text] [Related]
5. Clonal evolution during metastatic spread in high-risk neuroblastoma.
Gundem G; Levine MF; Roberts SS; Cheung IY; Medina-Martínez JS; Feng Y; Arango-Ossa JE; Chadoutaud L; Rita M; Asimomitis G; Zhou J; You D; Bouvier N; Spitzer B; Solit DB; Dela Cruz F; LaQuaglia MP; Kushner BH; Modak S; Shukla N; Iacobuzio-Donahue CA; Kung AL; Cheung NV; Papaemmanuil E
Nat Genet; 2023 Jun; 55(6):1022-1033. PubMed ID: 37169874
[TBL] [Abstract][Full Text] [Related]
6. Human neuroblastoma demonstrating clonal evolution in vivo.
Gotoh T; Sugihara H; Matsumura T; Katsura K; Takamatsu T; Sawada T
Genes Chromosomes Cancer; 1998 May; 22(1):42-9. PubMed ID: 9591633
[TBL] [Abstract][Full Text] [Related]
7. Activating mutations in ALK provide a therapeutic target in neuroblastoma.
George RE; Sanda T; Hanna M; Fröhling S; Luther W; Zhang J; Ahn Y; Zhou W; London WB; McGrady P; Xue L; Zozulya S; Gregor VE; Webb TR; Gray NS; Gilliland DG; Diller L; Greulich H; Morris SW; Meyerson M; Look AT
Nature; 2008 Oct; 455(7215):975-8. PubMed ID: 18923525
[TBL] [Abstract][Full Text] [Related]
8. Neuroblastoma.
Nakagawara A; Li Y; Izumi H; Muramori K; Inada H; Nishi M
Jpn J Clin Oncol; 2018 Mar; 48(3):214-241. PubMed ID: 29378002
[TBL] [Abstract][Full Text] [Related]
9. More than the genes, the tumor microenvironment in neuroblastoma.
Borriello L; Seeger RC; Asgharzadeh S; DeClerck YA
Cancer Lett; 2016 Sep; 380(1):304-14. PubMed ID: 26597947
[TBL] [Abstract][Full Text] [Related]
10. Cell death-based treatment of neuroblastoma.
Valter K; Zhivotovsky B; Gogvadze V
Cell Death Dis; 2018 Jan; 9(2):113. PubMed ID: 29371588
[TBL] [Abstract][Full Text] [Related]
11. [Genetic alterations in neuroblastoma and their usefulness for clinical management].
Normand C; Michon J; Janoueix-Lerosey I; Delattre O; Schleiermacher G
Bull Cancer; 2011 May; 98(5):477-88. PubMed ID: 21609891
[TBL] [Abstract][Full Text] [Related]
12. Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.
Chen L; Humphreys A; Turnbull L; Bellini A; Schleiermacher G; Salwen H; Cohn SL; Bown N; Tweddle DA
Oncotarget; 2016 Dec; 7(52):87301-87311. PubMed ID: 27888620
[TBL] [Abstract][Full Text] [Related]
13. Metastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling.
Pandian V; Ramraj S; Khan FH; Azim T; Aravindan N
Stem Cell Res Ther; 2015 Feb; 6(1):2. PubMed ID: 25888913
[TBL] [Abstract][Full Text] [Related]
14. Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma.
Vanichapol T; Chutipongtanate S; Anurathapan U; Hongeng S
Biomed Res Int; 2018; 2018():1812535. PubMed ID: 29682521
[TBL] [Abstract][Full Text] [Related]
15. Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma.
Burga RA; Yvon E; Chorvinsky E; Fernandes R; Cruz CRY; Bollard CM
Clin Cancer Res; 2019 Jul; 25(14):4400-4412. PubMed ID: 31010834
[TBL] [Abstract][Full Text] [Related]
16. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations.
Eleveld TF; Oldridge DA; Bernard V; Koster J; Colmet Daage L; Diskin SJ; Schild L; Bentahar NB; Bellini A; Chicard M; Lapouble E; Combaret V; Legoix-Né P; Michon J; Pugh TJ; Hart LS; Rader J; Attiyeh EF; Wei JS; Zhang S; Naranjo A; Gastier-Foster JM; Hogarty MD; Asgharzadeh S; Smith MA; Guidry Auvil JM; Watkins TB; Zwijnenburg DA; Ebus ME; van Sluis P; Hakkert A; van Wezel E; van der Schoot CE; Westerhout EM; Schulte JH; Tytgat GA; Dolman ME; Janoueix-Lerosey I; Gerhard DS; Caron HN; Delattre O; Khan J; Versteeg R; Schleiermacher G; Molenaar JJ; Maris JM
Nat Genet; 2015 Aug; 47(8):864-71. PubMed ID: 26121087
[TBL] [Abstract][Full Text] [Related]
17. Neuroblastoma: the impact of biology and cooperation leading to personalized treatments.
Owens C; Irwin M
Crit Rev Clin Lab Sci; 2012; 49(3):85-115. PubMed ID: 22646747
[TBL] [Abstract][Full Text] [Related]
18. Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy.
Martinsson T; Eriksson T; Abrahamsson J; Caren H; Hansson M; Kogner P; Kamaraj S; Schönherr C; Weinmar J; Ruuth K; Palmer RH; Hallberg B
Cancer Res; 2011 Jan; 71(1):98-105. PubMed ID: 21059859
[TBL] [Abstract][Full Text] [Related]
19. Accumulation of segmental alterations determines progression in neuroblastoma.
Schleiermacher G; Janoueix-Lerosey I; Ribeiro A; Klijanienko J; Couturier J; Pierron G; Mosseri V; Valent A; Auger N; Plantaz D; Rubie H; Valteau-Couanet D; Bourdeaut F; Combaret V; Bergeron C; Michon J; Delattre O
J Clin Oncol; 2010 Jul; 28(19):3122-30. PubMed ID: 20516441
[TBL] [Abstract][Full Text] [Related]
20. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
Yang XH; Tang F; Shin J; Cunningham JM
BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
